Summary Cognitive function items are increasingly included in quality of life measures, and complaints of concentration and memory difficulties are often reported by cancer patients. The aim of this study was to examine the factors influencing patients' level of complaint by comparing subjective reports with objective test performance of a sample of adult lymphoma patients, disease-free and > 6 months after treatment. There was no significant difference between complainers and non-complainers in sociodemographic or clinical characteristics or in their performance on standard neuropsychometric tests of concentration and memory. Those reporting concentration and memory difficulties had significantly higher scores on measures of anxiety, depression and fatigue. This calls into question the validity of including cognitive function items in self-report quality of life measures. Patients who report concentration and memory difficulties should be screened for clinically significant and potentially remediable mood disorder. Objective testing remains the method of choice for assessing higher mental function.
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In a recent survey of psychosocial problems among a mixed group of cancer patients (Cull et al., 1995) , 49% complained of cognitive impairment, i.e. problems with concentration and/or memory, which were rated moderate to severe by 21%. The significance of this incidental finding was difficult to interpret in such an heterogeneous sample but of sufficient concern to stimulate further study in a setting in which transient pharmacological effects could be excluded.
In other patient populations, the ability to process information under pressure of time (as assessed by the Paced Auditory Serial Addition Task, PASAT) has proved to be an important predictor of rehabilitative outcome (Gronwall, 1977) . It is not clear whether the same holds true in oncology. Two recent studies van Tulder et al., 1994) have highlighted rehabilitation problems, particularly in regard to return to work, among disease-free lymphoma patients. In the study of van Tulder et al., the cancer survivors had returned to work but reported poorer work performance, i.e. decreased efficiency, than healthy controls. Neither of these rehabilitation studies included assessment of cognitive function.
Estimates of the prevalence of cognitive difficulties are likely to vary with the method of assessment. In a prospective study of newly diagnosed lymphoma patients, performance on objective memory testing was not significantly different from general population norms, and was unchanging over time in spite of the fact that 38% of the patients complained of at least transient memory impairment, which was persistent for half of them throughout the period of the study (Devlen et al., 1987) .
Studies in other patient groups have reported a weak relationship between subjective and objective memory impairment (Lincoln and Tinson, 1989) . It has been suggested that this low correlation invalidates the use of questionnaires as measures of memory (Herrmann, 1982) . This calls into question the validity of self-report data on cognitive function generated from quality of life (QL) measures in common use in oncology, e.g. the EORTC QLQ-C30 (Aaronson et al., 1993) (Sunderland et al., 1983) . The Rivermead Behavioural Memory Test (RBMT) (Wilson et al., 1991) differs from the majority of previously published memory tests in sampling behaviours characteristic of everyday life. Lincoln and Tinson (1989) found significant correlations between performance on this test and the selfreports of stroke patients.
Anxiety and depression may also be relevant. In a study of patients with epilepsy, those who complained of memory problems were significantly more depressed and anxious than non-complainers (Corcoran and Thompson, 1993) . In the study by Devlen et al. (1987) , lymphoma patients who were anxious or depressed were also more likely to report memory impairment, although this was not reflected in objective test scores.
Fatigue may also be important. A study of patients with chronic fatigue syndrome found that those with high levels of fatigue performed less well on a memory task even in the absence of depression (McDonald et al., 1993) . Fatigue is a common complaint among cancer patients during treatment (Smets et al., 1993) and among Hodgkin's disease patients in remission (Fobair et al., 1986 [1] [2] [3] [4] (not at all to very much) and combined to form the cognitive functioning scale on which linearly transformed scores ranged from 0 to 100. Overall health and quality of life are each rated 1-7 (very poor to excellent) and combined to form a global health status/QL scale that, with linear transformation, also ranges from 0 to 100. On both of these transformed scales a higher score represents a better level of functioning.
Hospital Anxiety and Depression Scale (HADS) Zigmond and Snaith (1983) originally reported anxiety and depression subscales separately using scores in the range 8 -10 to denote possible cases and > 11 to identify probable case-level disturbance. More recently, HADS has been shown to be the screening instrument of choice for detecting affective disorder in disease-free cancer patients (Ibbotson et al., 1994) . In this setting the recommended threshold score of 19 is applied to the total HADS score (anxiety + depression).
Multi-Dimensional Fatigue Inventory (MFI) This 20-item Dutch instrument has been pretested in English in a mixed group of patients receiving radiotherapy in our department (Smets et al., 1995a (Smets et al., , 1996 (Bentall et al., 1993) .
Memory aids Patients were also interviewed about the external aids and internal strategies they employ using the checklist of memory aids developed by Corcoran and Thompson (1993) .
Objective tests The National Adult Reading Test (NART) The NART (Nelson, 1991) consists of 50 phonetically irregular words which the patient reads aloud. The score obtained for the number of words read correctly has been shown to provide a reliable estimate of premorbid intellectual ability in adults suspected of suffering from intellectual deterioration.
Paced Auditory Serial Addition Task (PASA T) This test (Gronwall and Sampson, 1974) consists of an audiotaped random series of digits presented at constant speed, i.e one number per 2.0 s. The patient is required to add consecutive pairs of numbers. Concentration is required to perform this complex information-processing task correctly under the pressure of time. This brief test has proved to be sensitive to organic impairment. Scores are derived from the total number of correct additions in one series of 51 digits (maximum score=50) and compared with published norms (Roman et al., 1991 compared with published data using the two-sample t-test. In comparisons in which both variables have many categories, Spearman's rank correlation coefficient (ru) was used. When it was appropriate to do so, parametric testing was also carried out. In all cases the same results were found on non-parametric and parametric testing. Logistic regression was used to determine whether both HADS and fatigue scores were independent predictors of subjective complainers of concentration and memory difficulties. Multiple regression was used to determine whether both HADS and fatigue scores were independent predictors of the EORTC cognitive functioning scale.
Results
The sample Of 122 patients contacted, 15 (12%) declined to take part in the study. Four patients said that they felt too ill, four were well and did not wish to be reminded of their illness, i.e. by returning to hospital for tests, three were too busy and four gave no reason. One hundred and seven (88%) completed the selfreport measures sent to them, but 16 declined to attend for There were no significant differences betwee those who did, and did not, complain of memory problems in performance on RMBT. The median profile score for complainers was 18 (range 14-24, n= 14) and for noncomplainers was 19 (range 9-24, n = 77); Mann -Whitney z = 0.6, P = 0.5). The median screening scores were 8.5 (range 5-12, n=14) and 9 (range 3-12, n=77; Mann -Whitney z= 0.2, P= 0.9) respectively. Scores on the EORTC cognitive functioning scale were not correlated with scores on PASAT (r,=0.5, n=88, P=0.7) or on RMBT (profile: r =0.07, n=91, P=0.5; screening: r,=0.01, n=91, P=0.9).
The relationship of subjective complaints of cognitive dysfunction to anxiety, depression and fatigue The significant differences in scores on anxiety, depression and fatigue scales between those who did and did not complain of concentration and memory difficulties are shown in Table III aids, e.g. lists (median 5, range 2-7; z = 3.4, P = 0.0006), and more internal strategies, e.g. alphabetical searching, mental retracing (median 3, range 1-6; z = 2.6, P = 0.008), than noncomplainers (external aids: median 3, range 0 -6; internal strategies: median 2, range 0 -5). Similarly, those who complained of memory difficulties reported using more external aids (median 4, range 2 -6; z = 3.2, P = 0.001) and internal strategies (median 3, range 1-6; z = 2.71, P = 0.007) than non-complainers (external aids: median 3, range 0 -7; internal strategies median 2, range 0-5).
Scores on the cognitive functioning scale were correlated with the number of external aids (r,= 0.49, n=91, P<0.0001) and internal strategies (r. = 0.32, n = 91, P= 0.002) used to assist memory.
Cognitive Regression analysis was therefore carried out using the HADS and fatigue scale scores to predict subjective complaints of concentration and memory difficulties. The MFI mental fatigue scale and 'caseness' on the HADS depression scale independently predicted complaints of concentration and memory difficulties and scores on the EORTC cognitive functioning scale (Table IV) .
Discussion
The EORTC QLQ-C30 is increasingly widely used internationally as an outcome measure in cancer clinical trials. Its cognitive functioning scale has not until now been validated against objective test data. It is, therefore, not clear what subjective complaints of concentration or memory difficulties derived from this scale actually mean.
Cancer patients' cognitive function may be compromised by organic impairment attributable to the disease process or treatment. These effects may be temporary and reversible; however, if the cognitive dysfunction complained of is associated with persistent difficulties in everyday living, this information deserves greater prominence in the reporting of treatment outcomes. On the other hand, complaints of cognitive difficulties may reflect psychological distress or fatigue, which are recognised as common among cancer patients. This distinction has important implications for the type of intervention that should be offered. Techniques may be taught to try to limit the problems caused by organic memory impairment, e.g. use of external memory aids, but mood disturbance is amenable to potentially curative intervention and warrants direct attention.
Patients treated for Hodgkin's disease and many patients with non-Hodgkin's lymphoma have an excellent prognosis in terms of survival, but the quality of their functional recovery has been called into question (van Tulder, 1994; Razavi et al., 1993) , and cognitive dysfunction may be a relevant factor. This patient population, therefore, offers the opportunity to examine the relationship between subjective complaints of concentration and memory difficulties and performance on objective testing in a setting in which the impact of active disease process and transient pharmacological effects can be excluded and the issue has clinical significance for patients' quality of life.
Difficulties were anticipated in tracing and recruiting longterm cancer survivors for a hospital-based follow-up study. We were greatly helped by access to the Scotland and Newcastle Lymphoma Group Register. The response rate was excellent, with only 12% of those contacted declining to participate. The reasons given ranged from 'feeling too well' to 'not feeling well enough', suggesting no systematic sampling bias in our data. Subjective complaints of concentration and/or memory difficulties were more common among those agreeing to undergo testing, and although the low prevalence of complaints was clinically encouraging this meant that the study had low power to detect differences between those who did and did not complain. Replication in a larger sample is needed.
The mean estimated IQ of those tested was relatively high, but there was no evidence that the estimated level of intellectual ability was associated with subjective complaints of concentration or memory difficulties.
The objective testing procedure was carefully chosen to be brief and user friendly, to encourage participation and yet to be sufficiently sensitive to act as a screen for organic impairment.
Subjective complaints of memory problems were compared with performance on the RBMT, which was specifically designed to reflect memory skills used in daily life. Scores on RBMT relate significantly to conventional memory tests but correlate better with patients' and relatives' reports of dysfunction than conventional measures (Lincoln and Tinson, 1989) . Subjective complaints of concentration difficulties were compared with performance on the PASAT. This test, which requires divided attention, sustained concentration and efficient information processing, has been shown to be sensitive to subtle neurocognitive deficits. In other patient samples PASAT scores have been found to mirror patients' self-reported difficulties (Johnson et al., 1994 (Fobair et al., 1986; Smets et al., 1996) . Whether or not some common underlying physiological mechanism can be elucidated, this finding further underlines the importance of assessing patients who complain of cognitive dysfunction or fatigue for clinically significant and potentially remediable emotional disturbance.
Contrary to expectations, complainers of concentration and memory difficulties reported using significantly more aids to memory, both external aids, e.g. lists, and internal strategies, e.g. mental retracing, than non-complainers. Having to use these aids may be viewed as an indicator of cognitive failure resulting in the observed self-reports of difficulties. Clinically, it would be wise to check whether these coping strategies are being used efficiently, but the primary action to relieve subjectively experienced problems in patients with no objective evidence of impairment focuses on addressing anxiety/depression.
As expected, those who reported better cognitive functioning also reported a better global quality of life.
On objective testing, this sample exhibited evidence of cognitive dysfunction in that the mean scores on the PASAT were lower than reference data from an older sample. In addition, 63% of the sample were identified by the RBMT screening score as memory impaired. These findings warrant further exploration.
The key point to emerge from this study is that what lymphoma patients in remission mean when they complain of concentration or memory problems on the EORTC QLQ-C30 cannot be measured on well-validated objective measures of concentration or memory. Their subjective reports appear to reflect affective disorder and mental fatigue. While this finding needs to be replicated in a larger sample of patients with complaints about their cognitive function and among those with different disease sites, treatment histories etc., it does call into question the validity of such a brief cognitive function scale.
Validity may be improved by the inclusion of additional items about specific aspects of cognitive function exemplified in activities of daily living. In other settings, it has been suggested that patients' subjective reports of their cognitive function should be collected in diary format and that relatives'/carers' reports are more reliable (Herrmann, 1982) . Until this can be demonstrated satisfactorily, objective performance testing remains the method of choice for assessing higher mental function.
